Fingerprint
Dive into the research topics of 'Phase I-II study of the farnesyl transferase inhibitor tipifarnib plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in HER2/neu-negative inflammatory carcinoma and non-inflammatory estrogen receptor-positive breast carcinoma'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically